AstraZeneca: Tagrisso shows promise in lung cancer
Tagrisso reduced the risk of disease progression or death by 84%, with a median PFS of 39.1 months versus 5.6 months for placebo.
Tagrisso extended progression-free survival by more than three years in this potentially curative setting, reinforcing the need to test and diagnose patients early", commented Susan Galbraith, Executive Vice President, Oncology R&D at AstraZeneca.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction